Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | AGER | Q15109 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | PRKCI | P41743 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | DHODH | Q02127 | 2/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KDM6B | O15054 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29530139 | 1.00 | NAPRT (1.00) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| SCHEMBL181403 | 1.00 | NAPRT (1.00) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| SCHEMBL30792465 | 1.00 | NAPRT (1.00) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL28305203 | 0.98 | NAPRT (0.96) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| SCHEMBL27926024 | 0.98 | NAPRT (0.96) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| SCHEMBL27881680 | 0.98 | NAPRT (0.96) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL29398658 | 0.98 | NAPRT (0.96) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| Carbamic Acid SCHEMBL27881895 | 0.98 | NAPRT (0.96) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| Nitrous Acid SCHEMBL27649581 | 0.92 | NAPRT (0.85) | NAPRTKDM4ETDP1ALDH1A1ALOX15 | |
| Quinolinic Acid SCHEMBL28273991 | 0.91 | NAPRT (0.82) | NAPRTKDM4ETDP1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3158053-A1 | ACCELERATION OF MYCOBACTERIUM GROWTH | St. George's Hospital Medical School (GB) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015193688-A1 | ACCELERATION OF MYCOBACTERIUM GROWTH | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2015-12-23 | — | — | WO | disclosed |
| US-8163908-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-8093401-B2 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8088928-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2388263-A1 | Imidazo[2,1-b]thiazole derivatives as sirtuin modulators | Sirtris Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8044198-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110236429-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20110150917-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | US | disclosed |
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2008151434-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | NAPRT 252/4885KDM4E 1599/4885TDP1 1028/4885 |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | NAPRT 252/4885KDM4E 1599/4885TDP1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.